The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

Completed 120 enrolled Sun Yat-sen University

RandomizedParallel-groupSingle-blindTreatment

Summary

A randomized controlled trial to evaluate efficacy and safety of Thymosin-α1 administration in patients with HBV-related Acute-on-chronic liver failure.

Timeline

Start: 2017-04-10
Primary completion: 2019-06-02
Completion: 2019-07-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Thymalfasin	Peptide	1.6 mg	Subcutaneous

The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

Summary

Timeline

Drugs

Indications